Feltl & Company reiterates its Buy rating on Insulet PODD and increased its price target to $22.10 from $18.60 on better than expected guidance for revenues in 2012.
Feltl & Company notes, "Insulet reported EPS of ($0.30) versus our ($0.27) estimate and ($0.26) consensus. Reported revenue came in at $47.2 million versus our $47.0
million estimate and $47.4 million consensus. Management guided 2012 revenue to a range of $210-$225 million versus our previous $207.7 million estimate. In addition, the company guided to a cash operating loss of ($10) million to breakeven, which was below our previous estimate of $8.2 million."
PODD closed at $19.95 a share on Thursday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in